PER® Miami Breast Cancer Conference | Conference

Dr. Robson on the Potential Utility of Tucatinib in HER2+ Breast Cancer

March 6th 2020

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

March 6th 2020

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Can We Use Genomic Profiling Data to Influence Locoregional Treatment Decisions in Breast Cancer?

March 6th 2020

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

CTC Surveillance in Early-Stage Breast Cancer: What's Next?

March 14th 2019

Blood-based biomarkers offer great potential for use in the management of breast and other cancers.

A New Trio of Genes Enters the Risk Assessment Equation in Hereditary Breast Cancer

March 14th 2019

David M. Euhus, MD, discusses a new trio of genes entering the risk assessment equation in hereditary breast cancer.

Experts Say DCIS Requires Focus on Genomics and Microenvironment

March 13th 2019

Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.

New Strategies Shift Landscape in HR+ Metastatic Breast Cancer

March 12th 2019

There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

March 12th 2019

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Bridging the Knowledge Gap Between Biosimilars and Biologics in Breast Cancer

March 11th 2019

Since 2006, the European Medicines Agency has granted marketing authorization for more than 40 biosimilars, and, in less than 4 years, the FDA has approved 17, yet the knowledge gap in the understanding of biosimilarity poses a unique challenge to the agents’ assimilation into clinical practice and possible impact on access and cost savings, experts say.

Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer

March 11th 2019

The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.

Excitement Grows About Immunotherapy Potential in Breast Cancer

March 10th 2019

Although the first checkpoint inhibitor has just been approved for patients with breast cancer, findings from dozens of ongoing studies may eventually change the paradigm for large subsets of those with the malignancy.

Antibody-Drug Conjugates Make Headway in TNBC

March 10th 2019

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.

Awareness Critical for Identifying irAEs Early in Breast Cancer

March 10th 2019

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.

Dr. Rugo on 20-Year Span of Breast Cancer Advancements

March 10th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.

Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer

March 9th 2019

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.

Promising Debut for PARP Inhibitors Spurs Excitement for Future Therapy

March 9th 2019

The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.

Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups

March 9th 2019

The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.

CDK4/6 Inhibitors Play a Growing Role in Enhancing Endocrine Therapy

March 9th 2019

For more than 100 years, endocrine therapy has been used for the treatment of breast cancer; since that time, we have learned much about the role of estrogen in the biology of normal breast cancer development.

Treatment Tailoring Possible With Gene Expression Profiling

March 9th 2019

Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.

Dr. Mittendorf on FDA Approval of Frontline Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC

March 9th 2019

Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1